anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a mesenchymal stem cell composition for treating osteoarthritis and a preparation method and application thereof. In particular, one aspect of the invention relates to a composition useful for formulating a cell therapy composition comprising sodium chloride, sodium phosphate, water and the like. Further, the present invention relates to a cell therapy composition useful for the treatment of osteoarthritis and cartilage defects comprising: mesenchymal stem cells, human serum albumin, sodium hyaluronate, sodium chloride, sodium phosphate salt, water and the like. In addition, the present invention provides the use of the cell therapy composition for the preparation of a medicament for the treatment of osteoarthritis and cartilage defects. In addition, the use of the aforementioned composition for the preparation of a cell therapy composition for the treatment of osteoarthritis and cartilage defects is also provided. The composition of the present invention and the cytotherapeutic composition can be used for treating osteoarthritis, and these compositions and cytotherapeutic compositions exhibit excellent technical effects as described in the present invention, for example, excellent stability and one or more excellent pharmaceutical effects.
This is A Single-center, Single-arm, Exploratory Clinical Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure.

In clinical practice, second-line liver cancer treatment still mainly relies on single-agent therapy, which may not provide additional clinical benefits for patients. On one hand, a real-world multicenter study published by ESMO in 2023 showed that the combination of ICIs and TKIs may still have potential efficacy in patients who progress after first-line targeted therapy for advanced liver cancer. Secondly, the combination of targeted therapy and local hepatic arterial infusion chemotherapy (HAIC) may provide a new opportunity for patients with advanced liver cancer who progress after targeted therapy. On the other hand, unlike PD-1 inhibitors, PD-L1 inhibitors can block the binding ability of PD-L1 with B7.1 on the surface of T cells, which is advantageous for comprehensive T cell activation. At the same time, PD-L1 monoclonal antibody only blocks the binding of PD-L1 with PD-1, preserving the function of PD-L2 and avoiding side effects such as interstitial lung disease (ILD), thus having better safety. Therefore, this study aims to explore the efficacy and safety of HAIC combined with PD-L1 and Regorafenib in patients with advanced liver cancer who have failed immunotherapy.
Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, have been reported (see WARNINGS ). 

Thrombocytopenia has occurred primarily with high dose intermittent therapy, but has also been noted after resumption of interrupted treatment. It rarely occurs during well-supervised daily therapy. This effect is reversible if the drug is discontinued as soon as purpura occurs. Cerebral hemorrhage and fatalities have been reported when rifampin administration has been continued or resumed after the appearance of purpura.

Rare reports of disseminated intravascular coagulation have been observed.

Leukopenia, hemolytic anemia, decreased hemoglobin, bleeding, and vitamin K–dependent coagulation disorders (abnormal prolongation of prothrombin time or low vitamin K–dependent coagulation factors) have been observed.

Agranulocytosis has been reported very rarely.
Participants will receive a single dose of INDV-2000. The starting dose is 1 mg with dose escalation dependent upon observed clinical safety, tolerability and pharmacokinetics.
UNLABELLED: Functional disability and chronic knee pain are frequent in combats sports participants. The McKenzie Method of Mechanical Diagnosis and Therapy (MDT) is a system for specific function examination and intervention for spinal and extremity musculoskeletal disorder. This clinical trial aimed to investigate the effectiveness of MDT, through Directional Preference, for specific function disability in Brazilian Jiu-Jitsu practitioners (BJJPs) experiencing chronic non-specific knee pain.
METHODS: Sixty-five BJJPs with chronic non-specific knee pain were evaluated and classified according to the MDT system. Following classification, 28 BJJPs were randomized pairwise into intervention (IG) and control (CG) groups. The procedures were consistent with the principles of DP and the intervention period was 6 weeks and follow up was included. The primary outcome was specific functional disability evaluated using the Patient Specific Function Scale (PSFS) and the secondary outcomes were pain intensity and fear-avoidance in utilizing the symptomatic limb. Data were analyzed with a two-way analysis of variance (ANOVA) and repeated measures for the outcome factor were performed (p < 0.05).
RESULTS: For the specific functional disability, ANOVA revealed significant differences between groups based on group interaction and treatment factors (F (2, 52): 162,015; p < 0.001; η2: 0.208). The BJJPs allocated to the IG achieved significant improvements in specific functional disability, a mean difference of -4.36 (-5.01 to -3.72) post-interventional and -4.80 (-6.07 to -3.53) follow-up in the PSFS. Improvements in pain intensity and fear-avoidance were also achieved post-intervention and follow-up.
CONCLUSION: Intervention in accordance with DP promoted resulted in favorable outcomes for clinical effects on specific functional disability pain intensity, and symmetry index of the lower limbs. These findings suggest that intervention based on DP may be effective in the management of chronic knee pain in BJJPs.
PURPOSE:To provide the titled remedy containing mecobalamin as an active drug component. CONSTITUTION:A remedy for peptic ulcer can be prepared by using mecobalamin[a-(5,6-dimethylbenzimidazolyl)-Co-methylcobamide; dark red crystal or crystalline powder; slightly soluble in water and ethanol, and hardly soluble in acetone and ether] as an active drug component. It is recommended to administer the drug in high dose, preferably 1,500mug/day in 3 divided doses by oral administration. It may be combined with proper components necessary to form the preparation. An adjuvant (e.g. red pigment) may be added as a component of the remedy for the stabilization of mecobalamin. Mecobalamin has pharmacological activities such as erythrocyte-proliferating, hemoglobin biosynthesis-promoting, sensory never-conduction suppressing, nervous restoration, myelination-promoting activities, etc.
Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
The invention relates to a plaster for treating lumbar and belongs to a pure Chinese medicinal preparation. The plaster comprises the following components in part by weight: 1 to 5 parts of common monkshood mother root, 1 to 5 parts of kusnezoff monkshood root, 1 to 5 parts of heracleum, 1 to 5 parts of dahurian angelica root, 1 to 5 parts of rhubarb, 1 to 5 parts of largehead atractylodes rhizome, 1 to 5 parts of Chinese angelica, 1 to 5 parts of achyranthe bidentatae, 1 to 5 parts of eucommia bark, 1 to 5 parts of suberect spatholobus stem, 1 to 5 parts of Chinese loive, 1 to 5 parts of radix gentianae macrophyllae, 1 to 5 parts of pangolin scales, 1 to 5 parts of atraotydin, 1 to 5 parts of officinal magnolia bark, 1 to 5 parts of cassia bark, 1 to 5 parts of liquoric root, 400 to 600 parts of pure soybean oil and appropriate amount of processed galenite. The manufacturing method comprises the following steps of: soaking the medicaments into the pure soybean oil; putting the medicaments into a sandy pot after soaking for enough days; decocting the medicaments over slow fire until the medicaments dry, and filtering out gruffs to prepare medicinal oil, mixing the medicinal oil and the processed galenite, decocting the mixture over slow fire; stirring the mixture until the mixture becomes sticky; dropping the mixture into water to become beads; collecting the beads into a porcelain container; and soaking the porcelain container into cold water for later use. The plaster has the effects of activating blood, freeing channels and network vessels, dispersing swelling and relieving pain. The plaster can be directly pasted on affected parts to make the medicament directly reach focus. The plaster has the advantages of consolidated effective rate, quick response, short treatment period, no side effect and convenient use. Clinical application proves that the plaster has the effective rate of 97.9 percent, significant efficiency of 95 percent and cure rate of 83.6 percent.
Cervical cancer (CC) is the fourth most common cancer among women worldwide. NLR Family CARD Domain Containing 5 (NLRC5) plays an important role in tumorigenesis. However, its effect and mechanism in CC remains unclear. In this study, we aimed to investigate the function of NLRC5 in CC. NLRC5 was found to be down-regulated in CC tissues compared with normal cervical tissues. However, patients with higher NLRC5 expression had better prognosis, patients with higher age, HPV infection, lymph node metastasis, recurrence and histological grade had worse prognosis. Univariate and multivariate analyses showed NLRC5 to be a potential prognostic indicator for CC. Pearson correlation analysis showed that NLRC5 might exert its function in CC through autophagy related proteins, especially LC3. In vitro experiments demonstrated that NLRC5 inhibited LC3 levels and promoted the proliferation, migration, and invasion of CC cells by activating the PI3K/AKT signaling pathway. Treatment with LY294002 reversed the above phenotype. Taken together, our finding suggested that NLRC5 would participate in cervical tumorigenesis and progression by regulating PI3K/AKT signaling pathway. In addition, NLRC5 and LC3 combined as possible predictors in CC.
Participants will receive Treatment A (mitapivat 100 milligram \[mg\] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
Participants will receive an isocaloric diet with a distribution of 50% carbohydrates, 30% fat and 20% protein for the two-week intervention. Additionally, they will receive a dietary supplement for the second week that will contribute another 10% of protein, obtaining 30% of protein consumption in the second week.
T2D poses a significant public health problem. Hyperglycemia is associated with a variety of vascular complications, but clinical trials of medication regimes designed to achieve near-normal HbA1c have been mostly negative. The lack of benefit observed in these trials may be due to the fact that they targeted HbA1c rather than glucose variability, and were conducted in patients with established T2D that had already experienced complications of the disease. In early T2D, management of postprandial glycemia may be particularly important for minimization of metabolic memory effects and preservation of beta cell function. Postprandial glycemia in early T2D is largely driven by dietary intake, but research findings that guide clinicians regarding the best dietary approach to prescribe are mixed. Studies done, to-date, have used one-size-fits-all dietary regimes that do not take into consideration the person's unique glycemic response to food. The investigators know from decades of research that behavioral methods are required to engage patients in lifestyle behavior change. The investigators argue that tailoring the approach to the participant's glycemic response and gut microbiome will enhance self-efficacy in ways that cannot be achieved through standard behavioral methods alone and, in turn, reduce glycemic variability and metabolic memory effects.

Co-PI Segal et al. demonstrated that subjects have high between-subject variability in postprandial response to the same food, suggesting that universal dietary recommendations are of limited utility for controlling elevated postprandial glucose. The machine learning algorithm devised by the group integrates multidimensional data to accurately predict personalized postprandial glycemic responses. In a subsequent validation study in 100 participants, they showed that a personally-tailored intervention based on the predicted response resulted in significantly improved postprandial glycemic response, and were accompanied by beneficial changes in gut microbiota.
Subjects in the low dose arm will receive a single administration of either 6x10\^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
Low QRS voltages (LQRSV), defined as a QRS amplitude from peak to nadir < 0.5 mV in all limb leads, are an emerging diagnostic finding on the electrocardiogram (ECG). In healthy individuals and athletes, LQRSV are rare (2.2-4% of elite athletes, 0.5% of recreational athletes, and 0.3% of sedentary individuals). LQRSV athletes commonly show ventricular arrhythmias (VAs) on exercise, and up to 40% of those with LQRSV and VAs have late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR). The prevalence of LQRSV in arrhythmogenic cardiomyopathy ranges from 17-40%, predicts left ventricular (LV) involvement, and is correlated with more extensive LGE replacement on CMR. In hypertrophic cardiomyopathy (HCM), LQRSV ranges from 0.7-11%. LQRSV-HCM patients have more segments with LGE, despite relatively smaller LV mass, suggesting a more advanced clinical stage and a worse prognosis. In dilated cardiomyopathy (DCM), LQRSV range from 6-7%, but may be higher (36%) in certain genetic forms of DCM. On a follow-up, LQRSV are independently associated with incident cardiac events, such as sudden death, sustained ventricular arrhythmia, or appropriate internal cardioverter defibrillator discharge. In cardiac amyloid, LQRSV range from 34-66% and demonstrate a negative prognostic value, with worse clinical outcomes regardless of underlying biologic, genetic, and clinical variables. In conclusion, LQRSV deserve careful consideration for exclusion of arrhythmogenic substrates in healthy individuals, athletes, and patients. While additional research is needed, it is reasonable that LQRSV should trigger clinical investigation to exclude underlying diseases at risk of life-threatening arrhythmias.
NEW MATERIAL:The azulene derivative of formula I (R<1> is 1-5C acyl, 2-5C alkyloxycarbonyl, carbamoyl, or carbamoyl or cyano having substituent on nitrogen atom; R<2> is 1-5C alkyl; R<3> is 1-6C alkyl, 6-9C aryl or 7-10C aralkyl). EXAMPLE:1-Methoxycarbonyl-3,6-diisopropylazulene. USE:Useful as a remedy for hyperlipemia. It has high activity and safety and usable as a preventive and remedy for hyperlipemia of human and other mammals. It can be administered orally or parenterally. PREPARATION:The compound of formula I can be produced by using a corresponding tropolone derivative as the starting substance, tosylating in the presence of a basic catalyst to obtain a 2-tosyloxytropolone derivative, reacting the compound with dimethyl malonate in the presence of methanolic alkali hydroxide and heating the obtained compound of formula II in the presence of a base.
The invention provides a congestion-eliminating pain-relieving plaster which is prepared from ligusticum, scorpio, centipede, stiff silkworm, lumbricus, pangolin scale, Chinese honeylocust spine, frankincense, and myrrh. Each plaster is preferably prepared from, by weight, 1.0g of ligusticum, 0.5g of scorpio, 0.5g of centipede, 0.5g of stiff silkworm, 1.0g of lumbricus, 0.5g of pangolin scale, 1.0g of Chinese honeylocust spine, 1.0g of frankincense, and 1.0g of myrrh. The congestion-eliminating pain-relieving plaster has the advantages of fine medicine material selection, rigorous formulation, fine process, and outstanding effect. The plaster is provided with the principle that in traditional Chinese medical science, mammary glands are masses caused by qi stagnation and blood stasis caused by long-time liver qi stasis, qi stagnation, and meridian blocking. Mammary glands are aggravated when angry and fatigue, and before premenstrual stage. When mammary glands last long, spleen and kidney are influenced. Kidney is in charge of Chong and Ren meridians. Menstrual disorder is caused by meridian blocking. The formula is consistent with traditional Chinese medical theories. The plaster has the functions of qi regulation, blood circulation activating, hard lump resolving, congestion eliminating, meridian activating, and pain relieving. Therefore, when the plaster is used, an effect is substantial, and a curative effect is reinforced. The plaster is a reliable method and medicine for treating mammary glands.
PROBLEM TO BE SOLVED: To obtain a silicon bath material which is used in contact with a body and which is effective for beauty and health. SOLUTION: This silicon bath material contains Si or SiOx (0<x<2) in an amount of >=30wt.% and further a salt in an amount of approximately two third of the weight of the Si or the SiOx . The Si or the SiOx is preferably charged into the negative ion. The particle diameters of the Si or the SiOx are preferably approximately 0.0001-7mm. When brought into a body, the silicon bath material can convert the positively charged site of the body into the negatively charged site to activate the blood, the cells and the body fluid. The silicon bath material can be applied to the slight to serious syndromes of headache, stiff shoulder, atopic dermatitis, digestive system diseases, circulatory system diseases, respiratory system diseases, nervous system and sense organ system diseases, nervous disorders, etc.  The contact of the silicon bath material with the body is performed, e.g. by a method comprising charging the bath material in a bath and subsequently taking the bath or by a method comprising scooping the silicon bath material with a vessel and subsequently applying the silicon material to the body.
Global Developmental Delay (GDD) is a disorder characterized by failure achievement of expected milestones in different areas of psychomotor development before 5 years of age. The estimated incidence of GDD is 1-3%, an early diagnosis and an efficacy treatment could provide a better long-term prognosis. Recent literature data have underlined the importance of early diagnosis followed by appropriate therapeutic management. In fact, GDDs could evolve into different neurodevelopmental disorders, especially if associated with other risk factors, such as intrauterine growth retardation, nutrient deficiencies, breastfeeding and maternal education, scarce social and economic conditions, poor learning opportunities, inadequate quality of caregiver-child interactions.

In recent decades, the use of virtual reality (VR) for therapeutic reason has become more and more popular for innovative treatments in cognitive-motor domain. Indeed, VR and the interactive playing can motivate children to learn new skills. Among the high-tech tools used in recent years for rehabilitation, the BTs Nirvana (BTsN) is one of the semi-immersive VR that can also be used in children, which allows to stimulate cognitive and motor domains. The aim of this single-blind, randomized, controlled study is to evaluate the feasibility and the effectiveness of integrated rehabilitation treatments with the use of BTsN in patient with Global Developmental Delay.
Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of personalized treatment for eating disorders based on their ecological momentary assessment surveys. Participants will complete one session of relapse prevention at the end.
The prevalence of obesity and morbid obesity in Taiwan has risen sharply in recent decades, as in other parts of the world, necessitating urgent action to prevent and curb its detrimental effects. Asian populations are susceptible to the repercussions of obesity at a lower body weight. A higher BMI is associated with more frequent outpatient visits, in-hospital admissions, higher medical costs, and a lower quality of life. However, effective weight management approaches are unlikely to be maintained in the long term without assimilation into daily lifestyle practices. This qualitative study, based on semi-structured interviews with 14 doctors, dieticians, and nurses who work to control the weight of people with obesity, explored and identified multilevel barriers in the context of daily life to improve the efficacy and execution of weight management strategies. They considered diets, physical activity, and sleep as key weight management activities. The cultural and psychosocial aspects of daily life were observed to have an impact upon weight management, particularly family conflicts due to cultural dynamics and socially and culturally reinforced food practices. To improve population weight, less-recognised aspects need to be addressed alongside the inclusion of mental health specialists in weight management protocols and policy interventions to minimise obesogenic practices and create environments conducive to weight management.